IM Cannabis (IMCC) - 2025 Q4 - Annual Report

Financial Performance and Risks - The company incurred significant losses since inception and anticipates continued losses, with insufficient revenues from product sales, raising concerns about future profitability [47]. - The company has faced challenges related to securing necessary funds for its strategies, which may impact its operational cash flows [47]. - The company is exposed to various financial risks, including market risk, interest rate risk, foreign currency risk, credit risk, and liquidity risk, as detailed in Note 23 of the 2025 Annual Financial Statements [699]. Ownership and Consolidation - The company has a 74% ownership stake in Focus Medical Herbs Ltd. and acquired the remaining 26% in May 2025, indicating ongoing consolidation efforts [27]. Regulatory Environment - The company operates under various regulatory frameworks in Israel and Germany, which could impact its business operations and financial condition [33]. - The company is vulnerable to geopolitical and regulatory changes in the cannabis market, particularly in Israel and Germany, which could affect its business outlook [50]. - The company relies on maintaining cannabis licenses and any failure to do so could have a material adverse impact on its operations [47]. Market Strategy and Growth Opportunities - The company is focused on expanding its market share in the cannabis industry, particularly in Israel and Germany, where demand trends are anticipated to grow [35]. - The company anticipates future opportunities for growth in Europe, particularly in the cannabis sector, as regulatory environments evolve [35]. Operational Challenges - The company is subject to various risks, including regulatory compliance, supply chain disruptions, and competitive dynamics, which could materially affect its financial performance [33]. - The company aims to improve margins and manage liquidity, with expectations regarding revenue and operating efficiencies being closely monitored [35]. - The company faces challenges in enforcing U.S. judgments against its officers and directors in Israel or the U.S. due to its incorporation in British Columbia and the residency of its directors and officers outside the U.S. and Canada [53].